# Smart Nanoparticles Target Tumors with Precision mRNA Therapy Breakthrough delivery system reprograms immune cells to fight cancer more effectively. - **Source:** [Science Latest](https://brifing.si/source/ebc20f22-8d1a-4ae4-ba4c-efcd0853ba19) - **Published:** 2026-09-16 - **Original article:** - **On Brifing:** https://brifing.si/s/b680446b-5af2-44bf-bd12-867f9d293d52 ## Tumor immunosuppression challenge Tumors create hostile environments that disarm cancer-fighting immune cells, even reprogramming macrophages to suppress immune responses. This immunosuppression remains a major barrier for immunotherapies. The study focused on tumor-associated macrophages that normally recruit T cells but become immunosuppressive when hijacked by cancer signals. Overcoming this microenvironment is crucial for treatment efficacy. ## mRNA payload mechanism The therapy delivers mRNA encoding CXCL9, a chemokine that recruits T cells. When macrophages take up these instructions, they switch from immunosuppressive to immune-activating states. The researchers combined this with resiquimod, a drug stimulating immune pathways. Lab tests showed macrophages began producing CXCL9 and other immune markers, with NOS2 expression increasing 89.5-fold while immunosuppressive signals decreased. ## Precision targeting innovation The 'smart' nanoparticles use antibodies targeting TREM2 proteins found exclusively on tumor-associated macrophages. This dual targeting ensures delivery only to immunosuppressive macrophages within tumors, not healthy tissues. The lipid nanoparticle technology builds on COVID vaccine platforms but adds this critical cell-specific homing mechanism to prevent systemic immune overactivation and dangerous side effects. ## Breast cancer mouse results In aggressive breast cancer models, three nanoparticle doses slowed tumor growth. Treated mice showed 4x higher CXCL9 concentration versus controls and detectable T-cell activity. The therapy reduced immunosuppressive macrophages by 63%. While not shrinking tumors further when combined with checkpoint inhibitors, it increased tumor-infiltrating T cells and lymph node responses - markers of potential durable immunity. ## Safety profile Initial studies detected no negative effects on other organs, though researchers emphasize need for further safety evaluation before human trials. The targeted approach minimizes off-target immune activation risks inherent in broader immunotherapies. This precision addresses a key challenge in cancer treatment: stimulating immunity specifically at tumor sites without systemic toxicity. ## Combination therapy insights When paired with existing checkpoint inhibitors, the treatment didn't enhance tumor shrinkage but created favorable immune changes. Increased diversity of T cells in tumors and lymph nodes suggests potential for longer-lasting responses. This indicates the therapy may work best as part of sequenced treatment regimens rather than standalone solutions. ## Technical advantages The platform combines three key innovations: mRNA reprogramming capability, tumor microenvironment targeting, and controlled immune activation. Unlike viral vectors, mRNA doesn't integrate into DNA and allows transient, dose-controlled protein expression. The TREM2 targeting mechanism could potentially be adapted for other macrophage-mediated diseases beyond cancer. ## Clinical translation pathway While promising, researchers caution significant work remains before human trials. Next steps include optimizing dosing, expanding to other cancer types, and developing GMP manufacturing. The study provides a blueprint for developing targeted immunotherapies that address tumor microenvironment resistance - a major limitation of current approaches. ## Sources covering this story - https://www.wired.com/story/smart-nanoparticles-deliver-mrna-directly-to-tumors-in-new-cancer-therapy/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._